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Abstract
Background: Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in
men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to
determine the effect of androgen deprivation therapy (ADT) on the bone mineral density (BMD) of men with
prostate cancer in Jamaica.
Methods: The study consisted of 346 Jamaican men, over 40 years of age: 133 ADT treated CaP cases (group 1),
43 hormone-naïve CaP controls (group 2) and 170 hormone naïve controls without CaP (group 3). Exclusion criteria
included metastatic disease, bisphosphonate therapy or metabolic disease affecting BMD. BMD was measured with
a calcaneal ultrasound and expressed in S.D. units relative to young adult men (T score), according to the World
Health Organization definition. Patient weight, height and BMI were assessed.
Results: Mean ± sd, age of patients in group 1 (75± 7.4 yrs) was significantly greater than groups 2 and 3 (67 ±
8.1 yrs; 65±12.0 yrs). There was no significant difference in weight and BMI between the 3 groups. . The types of
ADT (% of cases, median duration in months with IQR) included LHRH (Luteinizing hormone releasing hormone)
analogues (28.6%, 17.9, IQR 20.4), oestrogens (9.8%, 60.5, IQR 45.6) anti-androgens (11.3%, 3.3, IQR 15.2) and
orchiectomy (15.7%, 43.4, IQR 63.9). Unadjusted t score of group 1, mean ± sd, (-1.6± 1.5) was significantly less than
group 2 (-0.9±1.1) and group 3 (-0.7±1.4), p <0.001. Ninety three (69.9%), 20 (45%) and 75 (42%) of patients in
groups 1, 2 and 3 respectively were classified as either osteopenic or osteoporotic (p<0.001). Adjusting for age,
there was a significant difference in t scores between groups 1 and 2 as well as between groups 1 and 3
(p<0.001). Compared with oestrogen therapy and adjusting for duration of therapy, the odds of low bone mineral
density (osteopenia or osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3 to 3.4); with anti-androgens was 5.9
(95%CI, 32.7 to 5); with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multiple drugs was 9.2 ((95%CI, 31 to 7.1).
Conclusions: ADT is associated with lower BMD in Jamaican men on hormonal therapy for prostate cancer.
Introduction
Jamaica is a middle income country, situated in the tro-
pics, with a population of ~2.7 million and GNI per
capita of 4,870 [1]. Prostate cancer is the leading cancer
in Jamaican men, with an annual age-specific incidence
rate of 65.5 per 100,000 [2]. It is also the commonest
cause of male cancer-related deaths in Jamaica [3].
Despite the introduction of PSA screening in Jamaica in
1991, the disease continues to be detected at an advanced
stage [4-6]. The use of androgen deprivation therapy is
widespread in Jamaica. Common agents used are steroi-
dal and non-steroidal anti-androgens, leutenizing hor-
mone releasing hormone (LHRH) analogues, conjugated
oestrogens and bilateral orchiectomy.
Androgen deprivation therapy is associated with several
long-term complications [7]. Reduction in bone mineral
density (BMD) typically occurs within 6-12 months of
use of androgen deprivation therapy [8,9]. However pro-
longed use of androgen deprivation therapy is associated
with an increased fracture risk [10]. This correlates with
overall increased morbidity and reduced survival [11].
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formed with samples that were dominated by Caucasian
men from high income countries. Recent evidence sug-
gests an ethnic variation in the effects of ADT on BMD.
For example, Japanese men exposed to ADT have low
rates of osteoporosis [12] In general, men of African des-
cent have higher bone mass than Caucasian men, adjust-
ing for age [13]. Further, Afro-Caribbean men living in
tropical environments and in lower income countries are
likely to have different environmental exposures com-
pared with Caucasian men from high income countries,
which can influence BMD and the change in BMD with
age and therapy. We therefore sought to determine in a
sample of Jamaican men the effects of ADT on BMD.
Methods
Sample
The sample was recruited from men attending the urol-
ogy clinic at the University Hospital of the West Indies,
Mona, Jamaica from October 2008 – June 2009. Men
were eligible for recruitment if they were >40 years. The
men were divided into 3 groups:
Group 1- men with a histological diagnosis of prostate
cancer, non-metastatic, treated with androgen depriva-
tion therapy (surgical or chemical castration).
Group 2- hormonal naiive men with prostate cancer
(Treated with radical prostatectomy, external beam
radiation or active surveillance).
Group 3- hormone naiive men without prostate cancer.
Exclusion criteria included clinical or radiological evi-
dence of bone metastases, bonym e t a b o l i cd i s e a s ee . g .
Paget disease, hyperthyroidism, Cushing disease; renal
failure, prior bisphosphonate therapy or drugs affecting
bone metabolism.
Consent was obtained from the Ethics Board Commit-
tee, Faculty of Medical Sciences. All patients provided
written informed consent. The nature of androgen depri-
vation therapy was determined as well as the duration of
use. Types of androgen deprivation therapy included
steroidal and non-steroidal anti-androgens, LHRH analo-
gues, conjugated oestrogens and bilateral orchiectomy.
Patient co-morbidities were determined as well as a his-
tory of smoking and alcohol use. Bone mineral density
was measured with a calcaneal ultrasound. Weight (kg)
was measured using a beam balance, to the nearest 0.1kg
and height (m) was measured using standard technique
with a staidometer, to the nearest 0.1cm [14]. Weight
and height were measured and Body mass index (BMI)
was calculated as weight (kg)/ height (m)
2.
Bone mineral density assessment
Bone mineral density was evaluated quantitatively using
the Achilles Express calcaneal ultrasound machine.
BMD was expressed in standard deviation units relative
to young adult men (T score) according to the World
Health Organization definition (Normal: t score -1.0 or
greater, Osteopenia- t score between -1.0 and -2.5 and
Osteoporosis- t score -2.5 or lower).
Statistical analyses
Data are expressed as frequencies, means with sd or med-
ians with interquartile ranges as appropriate. For categori-
cal outcome variables, differences in proportions between
groups were tested with the Chi square statistic. For
normal distributed continuous outcome variables, differ-
ences between groups were tested by analysis of variance
(ANOVA) and for skewed continuous outcome variables
differences in distribution, were tested with the Kruskal-
Wallis procedure. Post Hoc comparisons following
ANOVA were performed using Scheffe’s method and post
hoc comparisons following the Kruskal-Wallis procedure
were done using Wilcoxon rank-sum test. Multivariate
regression analyses were used to assess differences in
BMD by group adjusting for age and anthropometry and
logistic regressions were performed to estimate the risk of
low BMD (osteoporosis or osteopenia) adjusting for age,
BMI or duration of drug therapy. The data was analyzed
with the Stata statistical software for Windows™ version
10(College Station, TX 77845, USA).
Results
Patient characteristics
Table 1 summarizes the patient characteristics. A total of
346 black Jamaican men were enrolled in the study.
Group classifications were as follows: group 1 (133
patients), group 2 (43 patients) and group 3 (170 patients).
Mean ± sd, age of patients in group 1 (75±7.4 yrs) was sig-
nificantly greater than groups 2 and 3 (67 ± 8.1 yrs;
65±12.0 yrs). There was no significant difference in weight
and BMI between the 3 groups.
Table 2 summarizes the frequency and duration of the
different modalities of ADT used. 34.6% of the sample
had exposure to multiple types of ADT. Of the patients
with single agent exposure, LHRH analogues were the
most frequently used method of ADT (28.6%); however
conjugated oestrogens had the longest duration of use
(60.5 mos).
BMD results
Unadjusted t score of group 1, mean ±sd, (-1.6± 1.5)
was significantly less than group 2 (-0.9±1.1) and group
3 (-0.7±1.4), p <0.001. Adjusting for age, there was a sig-
nificant difference in t scores between group 1 and
g r o u p s2a sw e l la sb e t w e e ng r o u p1a n d3( p < 0 . 0 0 1 )
Figure 1. Compared with group 3, and adjusting for age
and BMI, the odds of low bone density (osteoporosis or
osteopenia) was 0.36, (95%CI, 0.33 to 0.17) for group 1
and was 0.40 (95%CI, 0.52 to 0.22) Figure 2
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all drug classes were in the osteopenic range (<-1.0)
except for oestrogens (mean ±se; -0.65±0.45) and anti-
androgens (-0.88 ±0.40) Figure 3. Of the total sample of
men, 46% had a normal BMD. Osteoporosis or osteope-
nia was detected in (93) 70%, (20) 45% and (75) 42% in
groups 1, 2 and 3, respectively, p<0.001. Compared with
oestrogen therapy and adjusting for duration of therapy,
the odds of low bone mineral density (osteopenia or
osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3
to 3.4); with anti-androgens was 5.9 (95%CI, 32.7 to 5);
with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multi-
p l ed r u g sw a s9 . 2( ( 9 5 % C I ,3 1t o7 . 1 )F i g u r e4 .T h e r e
were no fractures noted during the study period.
Discussion
In this study, we report that men with prostate cancer
treated with ADT had significantly lower BMD com-
pared with hormone naïve men with prostate cancer
and controls without prostate cancer. All drug classes,
except oestrogens and anti-androgens resulted in a
reduced BMD. Additionally, we also found that a low
BMD was common in men with prostate cancer who
were hormonally naiive.
Several studies have documented progressive osteo-
porosis after treatment of prostate cancer with ADT
[8,15,16]. The difference was apparent from as early as
6-12 months of treatment. Longer duration of ADT
therapy increases the risk of bone complication [17]. In
our study, the rates of osteopenia compare favourably
with those seen in other studies, however the prevalence
rates of osteoporosis in all three groups studied our ser-
ies were lower than the prior documented studies. [17].
Morote et al detected osteopenia and osteoporosis in
45.3% and 41.5% of 53 men respectively, with prostate
cancer receiving prolonged ADT compared to 43.8%
and 28.1% of 57 men respectively, with prostate cancer,
not treated with ADT, p (osteoporosis) =0.162 [15]. Wei
et al documented osteopenia and osteoporosis in 38%
and 50% of 32 men respectively, treated with ADT for
over 1 year, compared to 38% and 25% of 8 men who
were hormonal naiive [16]. The high prevalence of low
BMD in men with prostate cancer, prior to the com-
mencement of ADT is in keeping with a prior cross-sec-
tional study of 41 men with prostate cancer [18].
Many studies regarding BMD have men of African eth-
nicity under-represented. The determinants of BMD in
persons of African descent is poorly studied and under-
stood. Results of the Tobago Bone Health Study revealed
that BMD was 10-20% higher in Afro-Caribbean males
than in United States non-Hispanic black and white
males [13]. Postulated differences in BMD due to ethni-
city may be related to lifestyle factors, genetic differences,
peak bone mass acquisition and bone geometry [13].
Important lifestyle factors include increased physical
Table 1 Patient characteristics
Variables Group 1 Group 2 Group 3 p value
N 133 43 170
Age (yrs) 75±7.4
a,b 67±8.1 65±12.0 <0.0001
Weight (kg) 70.4±10.8 71.5±11.6 72.8±14.4 0.4
Height (cm) 166.5±6.8
b 169.4±6.8 169.6±7.3 0.006
BMI (kg/m
2) 25.4±3.9 25.0±3.9 25.2±4.2 0.8
T score -1.6±1.5
a,b -0.9±1.1 -0.7±1.4 <0.0001*
Normal Bone density† 40 (30) 23 (55) 95 (58) 158 (46)
Osteopenia† 56 (41) 18 (40) 59 (33) 133 (37)
Osteoporosis† 37 (29) 2 (5) 16 (9) 56 (17)
Values are mean±s.d.
†values are counts (%).
Group 1- prostate cancer patients receiving androgen deprivation therapy.
Group 2- prostate cancer patients, hormonally naiive.
Group 3- non prostate cancer patients; hormonally naiive.
BMI- Body Mass Index.
p value comparison of means by analysis of variance (ANOVA) with post hoc
comparisons by Scheffe.
a- Group 1 vs Group 2: p<0.005.
b- Group 1 vs Group 3: p<0.005.
c- Group 2 vs Group 3: p<0.005.
* p value comparison of ranks by Kruskal Wallis procedure with post hoc
comparisons by Wilcoxon test.
a- Group 1 vs Group 2: p<0.005.
b- Group 1 vs Group 3: p<0.005.
c- Group 2 vs Group 3: p<0.005.
Table 2 Types of Androgen deprivation therapy
Drug Class Frequency (%) Duration in months* T score† Osteopenia (%) Osteoporosis (%)
Median 25
th and 75
th percentile
Multiple drugs 34.6 17.4 9.3, 56.2 -1.8± 1.4 33 46
LHRH analogues 28.6 17.9 9.3, 29.6 -1.5± 1.5 42 24
Oestrogens 9.8 60.5 22.2,67.8 -0.7± 1.6 38 7
Anti-androgens 11.3 3.3 0.7, 15.9 -0.9± 2.2 33 27
Orchiectomy 15.7 43.4 15.7, 79.6 -1.8± 1.4 43 38
Values are percents.
† Values are means ± s.d.
*p <0.001: Overall comparisons of medians/ranks across drug classes.
Abbreviations- LHRH- Luteinizing hormone releasing hormone.
Multiple drugs- Exposure to 2 or more different types of androgens.
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Figure 2 Odds Ratio for low bone mineral density, adjusting for age and BMI. Low BMD; Osteoporosis and osteopenia. Group 1- prostate cancer
patients receiving androgen deprivation therapy. Group 2- prostate cancer patients, hormonally naiive. Group 3- non prostate cancer patients;
hormonally naiive.
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Several studies have suggested that African ethnicity may
be protective against skeletal related complication in use
of ADT, in men with prostate cancer [11,17].
The clinical consequences of low BMD in men with
prostate cancer are quite grave. Fracture risk is
increased in men with prostate cancer, treated with
ADT [10]. Skeletal complications lead to impaired qual-
ity of life, impaired mobility, increased medical costs
and reduced overall survival [11,19,21].
Our study had several limitations. We were not able
to analyze various metabolic, lifestyle or dietary factors
that could modify BMD loss. History of alcohol intake
and smoking were not reliably obtained in all patients,
and could not therefore be analyzed with BMD. How-
ever, weight and BMI, which are known to affect BMD,
did not affect t scores.
Our method of measurement of BMD utilized quanti-
tative ultrasound. Calcaneal ultrasound utilizes an ultra-
sound probe which is placed on the heel to measure
BMD. It is portable, inexpensive and does not utilize
ionizing radiation. BMD is commonly measured using
DEXA [22]. However, DEXA is expensive, not portable
and not universally available. Several studies have sug-
gested comparable results of DEXA and calcaneal ultra-
sound in other groups of patients [23,24].
As seen from prior reports, our study suggests a pro-
tective effect of oestrogens on BMD [25]. Historically,
oestrogens were used as the primary modality of andro-
gen suppression, however due to the thrombo-embolic
and cardiovascular toxicity; this agent fell out of favour.
In Jamaica however, oestrogens continue to be used as
first and second line therapy in patients with prostate
cancer, without these significant adverse effects. Due to
Figure 3 Age-adjusted t score by drug class.
Figure 4 The risk of low BMD (osteoporosis or osteopenia) adjusting for duration of therapy. Reference drug therapy =oestrogens.
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bone protective effects; it may be considered the pre-
ferred treatment of choice for ADT in a resource poor
country such as Jamaica. Due to the study design; we
were unable to determine the effect of duration of ADT
and appearance of changes in BMD. There were several
patients who had exposure to different modalities of
ADT during the study period. This may have been due
to changes in drug availability, increased drug cost or
rising PSA. However, the results were consistent, even
after excluding these patients.
To the best of our knowledge, this is the first report of
the effect of ADT on BMD of patients of African descent
with prostate cancer. Due to the widespread use of this
agent in Jamaica, and the morbidity of osteoporosis and
fractures, we would recommend similar local screening
guidelines in Jamaica. We would also like to perform
further prospective studies to compare the efficacy of cal-
caneal ultrasound and DEXA as screening methods in a
similar subset of patients.
Conclusions
ADT is associated with lower BMD in Jamaican men on
hormonal therapy for prostate cancer.
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